Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
325.40
+14.70 (4.73%)
Jan 7, 2026, 10:08 AM EST - Market open
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 4 analysts that cover Bio-Rad Laboratories stock have a consensus rating of "Strong Buy" and an average price target of $358.5, which forecasts a 10.17% increase in the stock price over the next year. The lowest target is $310 and the highest is $409.
Price Target: $358.5 (+10.17%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 30, 2025.
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $350 → $375 | Strong Buy | Maintains | $350 → $375 | +15.24% | Oct 30, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $265 → $340 | Hold | Maintains | $265 → $340 | +4.49% | Oct 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $387 → $409 | Buy | Maintains | $387 → $409 | +25.69% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $245 → $265 | Hold | Maintains | $245 → $265 | -18.56% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $260 → $245 | Hold | Maintains | $260 → $245 | -24.71% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
2.61B
from 2.57B
Increased by 1.62%
Revenue Next Year
2.67B
from 2.61B
Increased by 2.26%
EPS This Year
10.08
from -65.36
EPS Next Year
10.30
from 10.08
Increased by 2.15%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.7B | 2.8B | |||
| Avg | 2.6B | 2.7B | |||
| Low | 2.5B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.4% | 8.2% | |||
| Avg | 1.6% | 2.3% | |||
| Low | -2.3% | -2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.84 | 11.40 | |||
| Avg | 10.08 | 10.30 | |||
| Low | 9.12 | 8.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 13.1% | |||
| Avg | - | 2.1% | |||
| Low | - | -19.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.